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This study was conducted in Iran in order to assess the distribution of CTX-M type ESBLs
producing Enterobacteriaceae. From January 2012 to December 2013, totally 198 E. coli,  139
Klebsiella spp, 54 Salmonella spp and 52 Shigella spp from seven hospitals of six provinces in
Iran  were screened for resistance to extended-spectrum cephalosporins. After identiﬁcation
and susceptibility testing, isolates presenting multiple-drug resistance (MDR) were evalu-
ated for ESBL production by the disk combination method and by Etest using (cefotaxime and
cefotaxime plus clavulanic acid). All isolates were also screened for blaCTX-M using conven-
tional PCR. A total of 42.92%, 33.81%, 14.81% and 7.69% of the E. coli, Klebsiella spp, Salmonella
spp and Shigella spp isolates were MDR, respectively. The presence of CTX-M enzyme among
ESBL-producing isolates was 85.18%, 77.7%, 50%, and 66.7%, in E. coli, Klebsiella spp, Salmonella
spp and Shigella spp respectively. The overall presence of CTX-M genes in Enterobacteriaceae
was 15.4% and among the resistant isolates was 47.6%. This study indicated that resistance
to  -lactams mediated by CTX-M enzymes in Iran had similar pattern as in other parts of
the  world. In order to control the spread of resistance, comprehensive studies and programs
are  needed.
© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is
an  open access article under the CC BY-NC-ND license (http://creativecommons.org/
in Enterobacteriaceae. CTX-M-type -lactamases constituteIntroductionThe emergence of new enzyme groups that have a typical
extended spectrum -lactamase (ESBL) resistance phenotype,
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but are non-TEM and non-SHV derivatives, have been reported
1a novel group of molecular class A ESBLs encoded by trans-
ferable plasmids. These enzymes exhibit overall preference
for cefotaxime (CTX; hence the name CTX-M) and ceftriaxone
Elsevier Editora Ltda. This is an open access article under the CC
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long with higher susceptibility to tazobactam than
lavulanate.1,2
The explosive dissemination of CTX-Ms around the world
as been referred to as “CTX-M pandemic” due to their
ncreasing description worldwide.3 These enzymes have
ifferent prevalence rates in various members of the Entero-
acteriaceae family. They mostly exist in enterobacterial
pecies such as Escherichia coli, Klebsiella pneumoniae, and
almonella enterica serovar Typhimurium. In contrast, produc-
ion of ESBLs is uncommon among the isolates of Shigella
onnei.4
Firstly, two CTX-M-type enzymes were reported in Europe
n 1989.5 But, they did not become predominant over the other
SBL enzymes until the ﬁrst decade of the XXI century, in
hich an extraordinary spread of these enzymes was observed
oth in hospital and community settings.6 Nowadays, a vari-
ty of different types of this enzyme has been identiﬁed.3 At
he time of writing this article, more  than 160 CTX-M-type
-lactamases have been identiﬁed in various clinical isolates
www.lahey.org/studies), classiﬁed in ﬁve families according to
he amino acid sequence: CTX-M-1, CTX-M-2, CTX-M-8, CTX-
-9, and CTX-M-25; two additional groups have been reported
ecently: CTX-M-74 and CTX-M-75,6 two of which (CTX-M-
 and CTX-M-8 types) are shown to be similar (95–100%) to
he chromosomally encoded -lactamase of Kluyvera ascor-
ata and Kluyvera georgiana,  respectively,7,8 while the original
ources of the other enzymes of this group remain unknown.
he blaCTX-M genes have been found on a number of plasmids
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and are commonly associated with IS mobile elements, such
as ISEcp1, found ﬂanking the open reading frame region of the
blaCTX-M genes.9
The CTX-M group has become the most common type
of ESBL in Latin America, but is also becoming more  com-
mon  in Europe and has been recently reported in the UK.3
Also, in Asia, previous reports have identiﬁed CTX-M produc-
ing isolates in China, Korea, Japan, and India.10 Resistance
to broad-spectrum -lactams is becoming an ever-increasing
problem in Iran.11 In this work, we investigate the distribution
of CTX-M-type enzymes in the clinical isolates of Enterobacte-
riaceae, including Escherichia coli, Klebsiella spp, Salmonella spp,
and Shigella spp in seven hospitals from six provinces of Iran.
Material  and  methods
This cross-sectional study was performed on the isolates col-
lected from seven hospitals of six provinces in Iran. They
included the provinces of Tehran, Kurdistan, Sistan and
Baluchestan, Mazandaran, Khuzestan, and Fars. Tehran iso-
lates were collected from two hospitals, namely Milad and
Mehr. The geographic distribution of the surveyed hospitals
and isolates collected from different provinces are shown in
Fig. 1 and Table 1, respectively. During the studied period,
totally, 198 Escherichia coli, 139 Klebsiella spp, 54 Salmonella spp,
and 52 Shigella spp were collected and used for further inves-
tigations. The studied samples included urine (mostly), blood,
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Table 1 – Total isolates collected from different provinces in Iran.
Bacteria Province
Tehran (Milad) Tehran (Mehr) Kurdistan Sistan and Baluchestan Mazandaran Khuzestan Fars Total
E. coli 78 14 37 30 6 25 38 198
Klebsiella spp 80 6 11 2 1 9 30 139
Salmonella spp 46 1 2 
Shigella spp 50 0 0 
sputum, wound, respiratory and vaginal secretions, ascites,
biopsies, and body ﬂuids. Identiﬁcation of the isolates was
done using conventional standard biochemical tests, includ-
ing plating in blood agar, chocolate agar, MacConkey agar,
Salmonella–Shigella agar (Merck, Germany), triple sugar iron
agar, urea agar, SIM medium, and IMVic  (indole, methyl red,
Voges-Proskauer, and citrate).12
ESBL  conﬁrmatory  test
To conﬁrm ESBL production, those isolates that were iden-
tiﬁed as resistant to ceftriaxone using the disk diffusion
susceptibility test were further subjected to the disk combina-
tion method.13,14 The combination disk method utilized discs
containing only cefotaxime (CTX) (30 mg)  and other disk con-
taining cefotaxime (CTX) (30 mg)  combined with clavulanic
acid (CLA) (10 mg)  (MAST Diagnostics, Merseyside, UK). ESBL
producing isolates were identiﬁed as those with a greater than
5 mm increase in the zone with the single antimicrobial com-
pared with the combined antimicrobial, i.e. demonstrating
ESBL inhibition.15
Antimicrobial  susceptibility  testing
The antimicrobial susceptibility test was done by Kirby-
Bauer disk diffusion methodology according to the guidelines
of Clinical and Laboratory Standards Institute.16 Antibi-
ogram was done for tetracycline (30 g), ampicillin (10 g),
amoxicillin (20 g), cephalothin (30 g), gentamicin (10 g),
amikacin (30 g), cefotaxime (30 g), ceftazidime (30 g),
ceﬁxime (30 g), imipenem (10 g), ciproﬂoxacin (5 g), and
antibiotics (MAST Diagnostics, Merseyside, UK).
To assess the effectiveness of the antibiotic concentration
gradient, E-test (AB Biodisk, Dalvagen, Sweden) using the cefo-
taxime concentration gradient strips was applied. For this
purpose, E-test was studied in a medium containing clavu-
lanic acid (4 g/ml) and a simple medium simultaneously. The
expected reduction in MIC  in the presence of the -lactamase
inhibitor was ≥3 log2 dilution steps.17
Polymerase  chain  reaction  (PCR)
Isolates with an ESBL phenotype were further investigated for
blaCTX-M alleles. Bacterial DNA was extracted from the iso-
lates by boiling the bacterial suspensions. DNA isolates with
the concentration of 0.1 ng/l were used as the templates for
PCR analysis. PCR was done by CINNAGEN MsterMix (Cinna-
clon, Iran), which was performed with the universal primers0 0 4 1 54
0 0 2 0 52
CTX-M-U1 (5′-ATG TGC AGY ACC AGT AAR GTK ATG GC-3′) and
CTX-M-U2 (5′-TGG GTR AAR TAR GTS ACC AGA AYC AGC GG-
3′), as described previously.18 Ampliﬁcation was carried out
in a Techne TC-512 thermocycler (Eppendorf, Hamburg, Ger-
many)  as follows: 30 cycles of 50 s for denaturation at 94 ◦C,
50 s for annealing at 58 ◦C, and 50 s for primer extension at
72 ◦C, followed by terminal extension at 72 ◦C for 10 min. Initial
denaturation at 95 ◦C for 5 min  was used for both ampliﬁca-
tions. Electrophoresis of PCR products was performed on 1%
agarose gel. The gel staining was performed in ethidium bro-
mide for 20 min  and visualized in gel documentation system
(Bio-rad, Hercules, USA).
Sequencing
To conﬁrm PCR products, sequencing was randomly done for
114 isolates by Takapozist Company, Iran (on behalf of Bioneer
Company, Korea). All the sequencing results were interpreted
by LaserGene software (DNASTAR, MADISON) including Seq-
Man, MegAlign, and EditSeq software.
Statistical  analysis
Statistical analysis was performed in SPSS 12.0 (SPSS, Chicago,
IL, USA). The variables were analyzed by univariate analy-
sis using v2 or Fisher’s exact test, as appropriate. Statistical
signiﬁcance was set at p < 0.05.
Results
During the studied period, 198 E. coli, 139 Klebsiella spp,
54 Salmonella spp, and 52 Shigella spp were totally investi-
gated. In the present study, MDR  was deﬁned as acquired
non-susceptibility to at least one agent in three or more
antimicrobial categories. A total of 42.92%, 33.81%, 14.81% and
7.69% of the E. coli, Klebsiella spp, Salmonella spp and Shigella spp
isolates were MDR, respectively. Increasing the diameter of the
disk containing -lactamase inhibitor (over 5 mm)  represents
the production of ESBL enzymes, whose data are shown in
Table 2. The CTX-M was detected in 15.4% of the isolates and
the presence of this gene in all of the resistant isolates was
47.6%.
Among E. coli isolates from the provinces of Fars, Sistan
and Baluchestan, Kurdistan, Mazandaran, and Tehran’s Mehr
hospital, 100% of ESBL-producing isolates were CTX-M posi-
tive. Also, 50% of Kurdistan and 75% of Tehran’s Milad hospital
were CTX-M positive. Totally, 88.37% of the MDR  and ESBL pos-
itive E. coli isolates (cephalosporinase) contained CTX-M and
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Table 2 – Test result of E-test and double-disk diffusion for diagnosis of ESBL-producing and
Cephalosporinase-producing isolates.
Bacteria: Total isolates Resistant (%) ESBL producing in
resistant isolates
Total ESBL producing
isolates
Cephalosporinase producers
in resistance isolates
E. coli 198 85 (42.92%) 54 (63.52%) 54 (27.27%) 45 (52.94%)
Klebsiella spp 139 47 (33.81%) 36 (%6.59%) 36 (25.9%) 32 (68.08%)
Salmonella spp 54 8 (14.81%) 2 (25%) 2 (25%) 3 (75%)
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onsisted of 46.91% of the total MDR  isolates detected by PCR
echnique. In the case of Klebsiella spp, 87.09% of the MDR iso-
ates were ESBL-producing and contained CTX-M genes, which
onsisted of 56.25% of the total MDR  isolates. Among ESBL-
roducing Salmonella spp isolates, 50% contained CTX-M gene
hat consisted of 14.28% of the total MDR  isolates.
Totally, out of 52 Shigella spp isolates, 7.69% were MDR,
.77% of which was ESBL-producing. All the patients with
rug resistance were under 10 years old and all resistant iso-
ates were related to Tehran’s Milad Hospital. Seventy-ﬁve
ercent of the resistant isolates belonged to male and 25%
ere female, and all the isolated bacteria were from stool.
n the resistant isolates, 100% were resistant to ampicillin,
moxicillin, cephalothin, gentamicin, and ceftazidime. Also,
5% and 50% were resistant to tetracycline and ceftizoxime,
espectively. All the isolates were sensitive to ciproﬂoxacin
nd imipenem. Seventy-ﬁve percent of the resistant isolates
ad ESBL-producing enzymes that were identiﬁed by the
ouble disk diffusion method. All ESBL-producing isolates
ere determined by cefotaxime E-test for cephalosporinase
roduction and the results of all the isolates were pos-
tive. In the genomic analysis of resistant genes, 75% of
SBL-producing Shigella spp isolates or nearly 50% of the
DR  isolates contained CTX-M gene. Also, the sequencing
esults indicated that CTX-M15 present in all the isolates was
xamined.
iscussion
n the present study, we  examined the presence of ESBL-
roducing isolates and identiﬁcation of CTX-M enzymes
nvolved in resistance to third-generation cephalosporins as
ossible. This study showed that resistance to -lactams
ediated by CTX-M enzymes in Iran had similar pattern as
n other parts of the world.
There are different reports from different geographical
egions on the speciﬁc focus of multi-drug resistance.19 So, to
etermine the prevalence of resistance in Iran, we decided to
valuate the occurrence of such resistance from different parts
f the country. The presence of CTX-M in all of the resistant
solates was 47.6%, a rate that was similar to the prevalence
n the studies of other parts of the world. In a similar study
rom South Korea on 603 Enterobacteriaceae, 6.8% of the total
solates and 44.1% of resistant isolates were carrying CTX-M
enes.20
There are different reports on the prevalence of these
nzymes in Enterobacteriaceae family from Iran and other
arts of the world. In a study from Tehran hospitals, ESBL3 (5.77%) 2 (25%)
production rate in Klebsiella pneumoniae was 72.1%, 45.2% of
which had blaCTX-M.21 Another study from Tehran on the clin-
ical isolates of E. coli revealed 56.69% production of ESBL,
35.78% of which was positive for blaCTX-M genes from the
CTX-M-I group and 2.1% was positive for blaCTX-M genes
from the CTX-M-III group.22 A study in Kurdistan Province
reported that 34.85% of Enterobacteriaceae family was ESBL
producing.23
The low number of ESBL-producing isolates in the present
study might be because of the diversity of clones examined in
this study. In the studies that have been done in other parts of
the world, different prevalence rates have been reported. The
prevalence of these enzymes in European countries for E. coli
and Klebsiella spp has been 5.4% and 23–25%, respectively.24
This rate is very low in Japan; i.e. in E. coli and Klebsiella spp, it
was less than 0.1% and 0.3%, respectively.13 In other parts of
Asia, 4.8% Korea,13 8.5% Taiwan,25 12% Hong Kong,26 and 28%
in Malaysia27 have been reported.
E. coli is the predominant pathogen that carries CTX-M
enzymes and the isolates carrying this gene are often isolated
in UTI, bacteremia, and gastroenteritis.28 In this study, the
most ESBL-producing E. coli carrying CTX-M genes was from
urine, bacteremia, respiratory infections, and gastroenteritis
isolates, respectively.
In the case of Klebsiella spp, CTX-M enzymes are important
after SHV and TEM. ESBL producing isolates can be isolated
from respiratory infections, intra-abdominal infections, and
blood ﬂow.28,29 But, in the present study, most of the ESBL-
producing Klebsiella carrying CTX-M genes were isolated from
the samples of urinary tract infections and respiratory tract,
wound, and blood. Sex distribution of the patients complied
with the kind of infections. Most isolates of E. coli were in
women with urinary tract infections. Conversely, most of the
patients with Klebsiella spp with respiratory infections were
men.
The presence of CTX-M enzyme among ESBL producing iso-
lates of E. coli, Klebsiella spp, Salmonella spp, and Shigella spp
was 85.18%, 77.7%, 50%, and 66.7%, respectively. In a similar
study in the United Kingdom and Ireland, similar results to
those stated in this study, i.e. 83% of ESBL-producing E. coli
and 74% of ESBL-producing Klebsiella, were found which were
due to CTX-M genes.30 It is obvious that -lactam resistance
due to CTX-M enzymes has similarly grown in Iran and other
parts of the world, which shows the need for comprehensive
studies and programs to control the spread of resistance.The frequency and distribution of CTX-M genes in differ-
ent geographic regions examined in this study showed that,
due to the indiscriminate use of new generation antibiotics in
the more  developed regions, a higher level of resistant genes
 i c r o
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was identiﬁed. As a statistical comparison of the rates of resis-
tant isolates of Tehran’s Milad Hospital and Medical Center
in Sanandaj (Kurdistan Province), signiﬁcant differences were
observed (p-value: 0.0007).
Certainly, as shown in the present study, comprehensive
control of antibiotics is extremely important. The most impor-
tant way to control the spread of resistance is control of
risk factors. The present study suggested the necessity for
identifying patterns of transmission and spread of antibi-
otic resistance in wider geographical areas and developing
a comprehensive program to manage and control the use of
antibiotics.
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